Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01908192 · ClinicalTrials.gov registry record · Phase 2
Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®
A Phase 2 study, sponsored by SyneuRx International (Taiwan).
- Terminated
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT01908192 is a Phase 2 study that was terminated before completion, run by SyneuRx International (Taiwan). The registered enrollment target is 60 participants.
The verdict
NCT01908192, a Phase 2 study, was terminated before completion, sponsored by SyneuRx International (Taiwan).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if NaBen® is a safe and effective add-on treatment for schizophrenia in adolescents.
Interventions
- DRUG Placebo
- DRUG NaBen®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2014-06 |
| Est. Completion | 2023-10-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01908192
The ClinicalTrials.gov registry entry for NCT01908192 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SyneuRx International (Taiwan), which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01908192 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01908192 about?
NCT01908192 is a clinical study titled "Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®". The purpose of this study is to determine if NaBen® is a safe and effective add-on treatment for schizophrenia in adolescents.
What is the current status of trial NCT01908192?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2014-06. Estimated completion is 2023-10-26.
What interventions are being tested in trial NCT01908192?
The interventions under investigation include: Placebo (DRUG), NaBen® (DRUG).
Who is sponsoring clinical trial NCT01908192?
This trial is sponsored by SyneuRx International (Taiwan), which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.